GENELUX CORPORATION Stock Issued During Period, Value, Other
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- GENELUX CORPORATION stock issued during period, value, other for the quarter ending 2024-12-31 was -$26.99M, a 10983.06% decline year-over-year.
- GENELUX CORPORATION stock issued during period, value, other for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- GENELUX CORPORATION stock issued during period, value, other for the quarter ending 2024-06-30 was $27.68M, a 2257.58% increase year-over-year.
- GENELUX CORPORATION stock issued during period, value, other for the quarter ending 2024-03-31 was $688.00K.
- GENELUX CORPORATION stock issued during period, value, other for fiscal 2025 was $224.00K, a 67.44% decline from fiscal 2024.
- GENELUX CORPORATION stock issued during period, value, other for fiscal 2024 was $688.00K, a 76.98% decline from fiscal 2023.
- GENELUX CORPORATION stock issued during period, value, other for fiscal 2023 was $2.99M, a 2390.83% increase from fiscal 2022.
- GENELUX CORPORATION stock issued during period, value, other for fiscal 2022 was $120.00K.
| Period end | Stock Issued During Period, Value, Other 3 month | Stock Issued During Period, Value, Other 12 month |
|---|---|---|
| 2025-12-31 | $224.00K 10-K · filed 2026-03-19 | |
| 2024-12-31 | -$26.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $688.00K 10-K · filed 2025-03-28 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $28.61M derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-06-30 | $27.68M 10-Q · filed 2024-08-14 | $30.18M derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-03-31 | $688.00K 10-Q · filed 2025-05-06 | $3.68M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $248.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $2.99M 10-K · filed 2025-03-28 |
| 2023-09-30 | $1.57M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $1.17M 10-Q · filed 2023-08-14 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $120.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $120.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |